Stefan Yee

chairman and non – executive director

Mr. Stefan Yee has more than 30 years of experience in audit, corporate law, mergers and acquisitions, corporate finance.

Mr. Stefan Yee has more than 30 years of experience in audit, corporate law, mergers and acquisitions, corporate finance, investment banking and private equity with companies as KPMG, Linklaters, the Flemish investment bank Lessius, the Belgian Corporation for International Investment (SBI/BMI), Beluga (Euronext Brussels) and as the founder and CEO of the PE Group, a Belgian privately held private equity firm. Stefan is, and has been an investor and/or board member of several listed and private companies such as, amongst others, Beluga, Encare group (Mensura), AXI, The Reference, Alro Holdings, Loomans Group, United Brands, Capco, Faseas International (Spacewell), HD Partners (Dekabo group), AED Rent, UnifiedPost Group, NRG New Generation, Axiles Bionics, including several healthcare companies (Docpharma (formerly Euronext Brussels), Uteron Pharma and Imcyse). Stefan holds Masters degrees in Law and Business Management from the Universities of Brussels (VUB and ULB Solvay Business School) and the University of Chicago (as a BAEF Fellow).

Leon Van Rompay

non – executive director

Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in.

Leon Van Rompay has more than 40 years’ experience in the pharmaceutical market. During his professional career he served in several positions including country & area manager (covering major territories) and board member of the Zambon Group. He was founder and CEO of Docpharma, a Belgian based generics company that was listed on Euronext and served on different boards including Ecodis and Uteron Pharmaceuticals. He was a founding member of BIGE/IBES (Belgian Institute for Health and Economics), the B.G.A. (Belgian Generic Association), BAPIE (Belgian Association of Parallel Import and Export) and was an executive committee member and board member of the Belgian Pharmaceutical Industry Association. He also was a member of the pharmaceutical deontological commission and responsible for this commission in the industry association executive committee.

Mélanie Mestdagt

independent director

Dr. Mélanie Mestdagt is a seasoned executive with over 20 years of leadership in the biotechnology and pharmaceutical industries. She currently serves as CEO of EyeD Pharma and UniD Manufacturing, two Belgian-based companies specializing in innovative long-acting drug delivery implants. Under her leadership, the companies have grown to nearly 100 employees and secured over €70 million in combined funding, while overseeing the development of new manufacturing facilities and guiding products from early-stage research through to market authorization.

Prior to her current role, Dr. Mestdagt held successive leadership positions at EyeD Pharma and Biofinance Consulting, and previously worked at Uteron and Actavis in R&D funding and strategic coordination roles. Her career began in academia, where she earned a PhD in Biomedical and Pharmaceutical Sciences from the University of Liège and conducted oncology research supported by FNRS Télévie.

She currently serves on the boards of AWEX (Wallonia Export-Investment Agency), the European Biotech Campus (EUBC), and is Vice-President of the BioWin Health Cluster. Dr. Mestdagt brings deep expertise in translational research, industrialization, regulatory strategy, and public-private financing in health innovation.

She is a Belgian national and holds a PhD and multiple degrees in biomedical sciences from the University of Liège.

Vincent Van Dessel

independent director

Vincent started his career in 1984 as a stockbroker at Cohen, De Greef, Van Dessel & C° in Brussels (Belgium) and later (1989) Van Dessel & C° in Antwerp (Belgium). In 1992, he joined the Brussels Stock Exchange (which became part of Euronext in 2000) as Markets and Listing Director and became member of the managing board Brussels Stock Exchanges (1998), member of the Executive Committee of Euronext NV (2000), member of the Management Board of NYSE Euronext and Chairman and CEO of NYSE Euronext Brussels (2009) and member of the Managing Board of Euronext NV and Chairman and CEO of Euronext Brussels (2014).

He served as Chairman of the Brussels Market Authority from 2000 to 2003 and was member of the Belgian Corporate Governance Committee from 2009 till 2023 and member of the Euribor Steering Committee from 2015 till 2020.

Recently, he has been appointed member of the Board of VFB (May 2024)

He is Licenciaat-Doctorandus in Applied Economics from the KULeuven University, Belgium and has been guest lecturer in several universities including the KULeuven, UCL, Lille University, Solvay Business School, HEC Liège Antwerp University and Paris Sorbonne.

He is born on 25 November 1958 in Mechelen, Belgium, married and father of twins born in 1990.

Revital Rattenbach

independent director

Seasoned entrepreneur in biotech with 15+ years of experience, Revital Rattenbach is the founding CEO of 4P pharma, a clinical stage biotech specialized in drug regeneration for treating severe diseases.

Under her CEOship, 4P Pharma assembled a unique circular drug development platform which delivered 2 programs in clinical stage while nurturing a furnished preclinical pipeline. She signed multiple academic and pharma collaborations worldwide and closed series of fundraising since 4P incorporation 8 years ago.

Prior to her role at 4P, Revital was the Head of PharmaSeed Europe (2013-2014) a research organization specialized in early development where she supervised all BD activities, finance and operations.

Prior to PharmaSeed, Revital started her entrepreneurship path by co-founding Adstem, a spin-off of Sorbonne University to activate endogenous adult stem cells. Revital is board member of Biosenic, listed company on Euronext Brussels and she holds a PhD in Biology from University of Paris VI and an MBA from Sorbonne University.

Stijn Van Rompay

chief executive officer & co-founder

Mr. Stijn Van Rompay has over 20 years of experience in leadership positions at various pharmaceutical companies.

Stijn co-founded and was the CEO of Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product sales. He was also co-CEO of Uteron Pharma, a company focused on innovative female healthcare products.

Prior to these positions, Stijn was CFO and later, CEO of Docpharma (formerly quoted on Euronext Brussels) a generics and medical-device company. Under his leadership, the companies recorded strong growth and value creation. He also holds several non-executive director positions in the biotech sector, and acts as an advisor to venture capital investors. Stijn holds a Master’s degree in Applied Economics from the University of Antwerp.

Thomas Jacobsen

chief business development officer & co-founder

Mr. Thomas Jacobsen has over 20 years of experience in the pharmaceutical industry, with expertise in operational management, business development, licensing, and research and development.

He co-founded Alter Pharma, a pharmaceutical company focused on the development of complex generics and pharmacy-related product distribution. Prior to this, he worked with Docpharma, a generics and medical-device company that was acquired by Matrix Laboratories/Mylan Laboratories, where he worked on out-licensing of Docpharma’s products. Thomas started his career in the Scandinavian-based generics company Alternova, where he was responsible for licensing, product registration and launches. Thomas holds a Master’s Degree in Pharmacy from the University of Copenhagen and a Business Degree from Copenhagen Business School.

Christophe Maréchal

Chief Financial Officer

Christophe Maréchal is an experienced executive with a strong background in financial and strategic leadership. With over 30 years of professional experience, he has held senior financial roles across various industries, including pharmaceuticals, EPC, telecommunications, glass manufacturing, and banking. His career includes key positions with major international organizations such as Orange and AGC, and Mithra Pharmaceuticals, providing him with valuable global exposure.

Christophe has expertise in corporate finance, equity fundraising, investor relations, mergers and acquisitions, tax planning, treasury, supply chain optimization, and financial risk management. He has developed and implemented strategies to drive long-term business growth and improve operational and financial performance.

He holds a Master of Business Administration in Commercial Engineering from the University of Liège, Belgium, and has studied econometrics at the Katholieke Universiteit Brabant in Tilburg, Netherlands.

Dietmar Aichhorn

chief operating officer

Dr. Dietmar Aichhorn, PhD, has over 20 years of experience in various scientific roles within the pharmaceutical industry.

Over the course of his career at Sandoz, Mylan, Innovacell, ViraTherapeutics and Polpharma Biologics, Dietmar has held several senior management positions of increasing responsibilities including Head Clinical Development and Head Development. Dr. Dietmar Aichhorn is an expert in the fields of technical development, clinical development and regulatory affairs in the US, EU and other key geographies. Most recently, Dietmar had an assignment at Polpharma Biologics, where he was responsible for the clinical development of monoclonal antibodies, as well as overseeing all scientific affairs. Dietmar graduated as chemical engineer in Linz but has perfected his project management skills at the university of Vienna.

Ann De Jaeger

Chief Legal Officer and General Secretary to the Board

Ann De Jaeger has over 25 years of international leadership experience in legal, governance, and corporate affairs.

Throughout her career, Ann has held senior executive and board-facing roles at multinational, listed, and family-owned companies in the FMCG and B2B sectors, including Danone, Alpro, Barco, and What’s Cooking Group. She has a strong track record in supporting business transformation, M&A, regulatory strategy, communication, and stakeholder engagement, serving as a trusted advisor to CEOs and boards on corporate governance, compliance, and risk management. Ann has played a leading role in major strategic transactions, company and product positioning, integrations, and divestitures, and has extensive experience in public affairs and ESG advocacy at European and international levels.

Ann holds a Master of Law from Ghent University, a Master in Business Law from the University of Antwerp, and has completed several leadership courses at IMD, MIT, and Vlerick. She is also a Certified Board Director and speaks Dutch, English, and French.

Grow with us

We are driven to continuously innovate existing medications and offer meaningful benefits to patients, physicians and payors.

Why join us

The key to success is an exceptional workforce. Great people generate great results. As a young, entrepreneurial company, Hyloris fosters creativity, courage, and professionalism.
At Hyloris you will be part of multicultural and multidisciplinary team who will support you to further develop and grow your personal skills.

We strive to create an exciting and dynamic working environment in which you will be challenged to take initiative, contributing to the success of the company.

Interested in joining our mission to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors? Check out our vacancies below.

We look forward to hearing from you.

Latest vacancies

Scientist Analytical Chemistry

Location: Belgium - Liège

view vacancy

We are currently looking for a Scientist Analytical Chemistry. The successful candidate will perform pharmaceutical laboratory operations in an entrepreneurial environment.

Job description
As a Scientist Analytical Chemistry your role and responsibilities will be to:

• Perform pharmaceutical laboratory operations in a start-up environment.
• Execute pharmaceutical analytical development work in guidance from Senior Scientist or lab manager or its designee.
• Support new laboratory operations and implement systems and process to ensure compliance & data integrity.
• Collaborate with Hyloris’ team of globally experienced scientists.
• Perform the laboratory activities for analytical development with minimum supervision.
• Participate in development of ongoing & new projects in parenteral and liquid oral dosage forms such as solution, suspension, and solid dosage forms such as oral tablets, capsules dosage form, etc.

Main tasks:
• Execute Analytical Test Plans, Specifications, method robustness studies, review or develop analytical method verification protocols, method validation protocols and report, etc.
• Execute the qualification, maintenance, calibration of all instruments and ensure compliance to data integrity.
• Perform standard analytical laboratory tasks such as Karl Fisher water content, Titrimetry, pH and Dissolution testing, etc.
• Carry out and support extensive Pre-formulation studies such as solubility, pH stability profile, compatibility, characterization using advanced analytical techniques such as HPLC, UV, DSC, XRD, PSD, SEM, etc
• Support the development and validation analytical methods using chromatographic (HPLC, GC) and spectroscopic techniques (UV) per ICH, USP, US FDA, EMA requirements.
• Execute laboratory operations, plan, schedule and implement experimental designs.
• Develop and validate analytical methods as per regulatory standards for all products in the pharmaceutical development pipeline based on requirement.
• Execute all experiments and record them in laboratory notebook support in preparation of analytical documents, protocols, study designs, reports.
• Execute pharmaceutical development lab studies, Participate in technology transfers, method transfers, method verifications and method validation work in compliance with GMP guidelines.
• Participate in review of Submission Documents for Pre-IND, IND, NDA, as well as Quality GMP documents such as SOP’s, OOS investigations, CAPA, etc.

Your professional profile
• Minimum Qualification: (Professional) Bachelor in Sciences (Chemistry, Pharmaceutical or allied / equivalent).
• Minimum Experience: +3 years industrial experience in pharmaceutical R&D.
• Languages: English [written and verbal] – French is an asset.
• Computer literate: MS office suite, Design Expert software (or equivalent), Basic statistical calculations.

Your abilities
• Demonstrates strong work ethics, and effective written and verbal communication skills.
• Strong analytical/formulation skills, good negotiator/diplomat, enabler.
• Strong interpersonal skills, a collaborative and trust enabling working style, building partnerships among key stakeholders. Good team player.
• Organizational aptitude to be part of an outstanding team.
• Adaptability, flexibility, independence, and resourcefulness to both lead a big vision strategy while also willing to roll-up-sleeves and multi-task to thrive in a growing environment.
• To have essential professional attributes include a detailed-oriented analytical thinking, a team-player attitude, respect and understanding for cultural differences in different countries, and efficient utilization of time and resources.

About Our Company
Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors.
Hyloris has built a broad, patented portfolio of reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Two products are currently in initial phases of commercialisation with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment.
The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks.
Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.

Our values
Our talented staff work in accordance with our company values:
• We are proud of our entrepreneurial culture and foster open communication, mutual respect, professionalism and efficient decision-making and we believe that our multicultural organisation is one of our most important competitive advantages.
• We believe that timely and well considered decisions as a response to emerging opportunities and ideas is the key to our success.
• We believe that the success of the company lies in the competence, dedication, and motivation of each of our employees.
• We believe that freedom returns flexibility and empowerment returns commitment.

For more information about our company, please visit www.hyloris.com. Motivation letter and CV can be sent to peter.mertens@hyloris.com

Apply